Generic drugmaker Teva Pharmaceutical Industries Ltd. (TEVA) Monday said it has commenced commercial launch of both irbesartan and irbesartan-hydrochlorothiazide tablets, the company's generic versions of Sanofi Aventis' high blood pressure treatments, Avapro and Avalide tablets.
The brand products had annual sales of around $464 million and $124 million, respectively, in the U.S., based on IMS sales data.
As the first company to file Abbreviated New Drug Applications containing paragraph IV certifications for both of these products, Teva has been awarded a 180-day period of marketing exclusivity.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org